- Home
- PVLA vs CELC Comparison
PVLA vs CELC Comparison
Compare PVLA & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- CELC
- Stock Information
- Founded
- PVLA 2015
- CELC 2011
- Country
- PVLA United States
- CELC United States
- Employees
- PVLA N/A
- CELC N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- CELC Medical Specialities
- Sector
- PVLA Health Care
- CELC Health Care
- Exchange
- PVLA Nasdaq
- CELC Nasdaq
- Market Cap
- PVLA 280.4M
- CELC 327.3M
- IPO Year
- PVLA N/A
- CELC 2017
- Fundamental
- Price
- PVLA $22.77
- CELC $10.15
- Analyst Decision
- PVLA Strong Buy
- CELC Strong Buy
- Analyst Count
- PVLA 7
- CELC 6
- Target Price
- PVLA $44.43
- CELC $30.17
- AVG Volume (30 Days)
- PVLA 82.1K
- CELC 190.9K
- Earning Date
- PVLA 05-15-2025
- CELC 05-14-2025
- Dividend Yield
- PVLA N/A
- CELC N/A
- EPS Growth
- PVLA N/A
- CELC N/A
- EPS
- PVLA N/A
- CELC N/A
- Revenue
- PVLA N/A
- CELC N/A
- Revenue This Year
- PVLA N/A
- CELC N/A
- Revenue Next Year
- PVLA N/A
- CELC N/A
- P/E Ratio
- PVLA N/A
- CELC N/A
- Revenue Growth
- PVLA N/A
- CELC N/A
- 52 Week Low
- PVLA $6.20
- CELC $7.58
- 52 Week High
- PVLA $29.27
- CELC $19.77
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- CELC 46.58
- Support Level
- PVLA N/A
- CELC $9.64
- Resistance Level
- PVLA N/A
- CELC $10.80
- Average True Range (ATR)
- PVLA 0.00
- CELC 0.66
- MACD
- PVLA 0.00
- CELC -0.06
- Stochastic Oscillator
- PVLA 0.00
- CELC 25.25
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.